Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL9870859 | 0.95 | MEN1 (0.52) | MEN1KMT2ATAAR1HRH3IDO1 | |
| SCHEMBL8361121 | 0.95 | MEN1 (0.55) | MEN1KMT2ATAAR1HRH3IDO1 | |
| SCHEMBL6557766 | 0.89 | MEN1 (0.73) | MEN1KMT2ATAAR1HRH3IDO1 | |
| SCHEMBL8099771 | 0.82 | TAAR1 (0.68) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL8092500 | 0.82 | TAAR1 (0.68) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL6083770 | 0.81 | TAAR1 (0.53) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL1610656 | 0.81 | TAAR1 (0.53) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL8086943 | 0.80 | TAAR1 (0.65) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL8092438 | 0.80 | TAAR1 (0.65) | TAAR1HRH3IDO1DAOFDPS | |
| SCHEMBL8093918 | 0.80 | TAAR1 (0.65) | TAAR1HRH3IDO1DAOFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384974-B2 | 4,5-dihydronaphtho[1,2-b]thiophene derivative | TAISHA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-10 | — | — | US | disclosed |
| US-20060189678-A1 | effective in reducing triglyceride levels in the liver and reducing blood glucose levels | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1650202-A1 | 4,5-DIHYDRONAPHTHO [1,2-b] THIOPHENE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-0500653-A4 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST INC (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0500653-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991006548-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-5008265-A | 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same | BIOCRYST, INC. (US) | 1991-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189678-A1 | effective in reducing triglyceride levels in the liver and reducing blood glucose levels | LIPC, PNLIP, MTTP | MEN1 4114/4885KMT2A 1781/4885TAAR1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.